The following post is from Federal Agency Weekly. It tracks federal grants policy issuances, rulemakings, guidance development and OIG reports and publications. The primary focus of Federal Agency Weekly is agency-wide grants management issues related to extramural research grants from NIH, NSF, NASA, and DOD, though broader coverage of NIH is provided with the inclusion of NIH program activities.

March 23-March 27, 2020

Discover Grants Management Webinars from Thompson Grants
See upcoming schedule ›

National Institutes of Health

• Now Posted: OLAW Webinar on Pandemic Contingency Planning and Its Impact on Animal Care
  
  
• 3/26/20 FR: Notice To Announce Request for Information on the Development of the National Institute of Diabetes and Digestive and Kidney Diseases Strategic Plan
  
  
• Policy Notices
  
  
• NOT-OD-20-091: UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)
  
  
• General Notices
  
  
• NOT-AI-20-040: Notice of Early Expiration of Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV), NOT-AI-20-030
  
  
• NOT-DA-20-043: Request for Information (RFI): Inviting Comments on the Establishment and Implementation of a Standard Unit Dose of Delta-9-tetrahydrocannabinol (THC) for Cannabis Research
  
  
• NOT-FD-20-019: FDA – Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
  
  
• NOT-FD-20-021: Notice of 2nd deadline extension for the 2020 Application Due Date for PAR-20-091 “Revision Applications – FSMA Human Foods Preventive Controls Implementation Expansion Supplement to RFA-FD-18-001 (U18 Clinical Trials Not Allowed)”
  
  
• NOT-HL-20-758: National Heart, Lung, and Blood Institute (NHLBI) Announces Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research
  
  
• NOT-HS-20-007: Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19
  
  
• NOT-HS-20-008: Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19
  
  
• Changes to Funding Opportunities
  
  
• NOT-CA-20-041: Notice to Extend the Submission Period to the National Cancer Institute (NCI) for PA-18-906, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed)
  
  
• NOT-EB-20-004: Notice of NIBIB’s Participation in PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”
  
  
• NOT-FD-20-018: Notice to correct Section II – Award Information for RFA-FD-20-030 – “Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional.”
  
  
• NOT-FD-20-020: Notice of Change to the 2020 Application Due Date and New Scored Review Criteria for Overall and Admin Components for PAR-20-105 titled “Laboratory Flexible Funding Model (LFFM) (U19) Clinical Trials Not Allowed”
  
  
• NOT-HG-20-033: Notice of Change of Receipt Date for Mendelian Genomics Research Centers (RFA-HG-20-007) and Mendelian Genomics Data Coordinating Center (RFA-HG-20-008)
  
  
• NOT-MD-20-015; Notice of NIMHD Withdrawal from Participation in PA-19-053, “NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  
  
• NOT-MD-20-016: Notice of NIMHD Withdrawal from Participation in PA-19-054, “NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  
  
• NOT-MD-20-017: Notice of NIMHD Withdrawal from Participation in PA-19-092, “NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  
  
• NOT-NS-20-043: Notice of Change to Key Dates for PAR-17-480 “NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44)”
  
  
• Notices of Special Interest
  
  
• NOT-AI-20-034: Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  
  
• NOT-CA-20-036: Notice of Special Interest (NOSI): Administrative Supplements for the Use of Existing Body Composition Data to Understand Treatment-Related Outcomes in Clinical Trials and Observational Studies
  
  
• NOT-CA-20-037: Notice of Special Interest (NOSI): Administrative Supplements for Understanding Aging Trajectories Among Cancer Survivors
  
  
• NOT-CA-20-039: Notice of Special Interest (NOSI): Administrative Supplements for Exploring the Intersection of Tobacco and Alcohol Use Behaviors for Cancer Control
  
  
• NOT-DA-20-018: Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related Processes
  
  
• NOT-DA-20-021: Notice of Special Interest (NOSI):Sleep and Substance Use Disorders
  
  
• NOT-DA-20-037: Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders
  
  
• NOT-ES-20-012: Notice of Special Interest: Hurricane Harvey Administrative Supplements
  
  
• NOT-GM-20-025: Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
  
  
• NOT-HD-20-003: Notice of Special Interest (NOSI): Availability of Administrative Supplements to Advance Safe and Effective Therapeutics in Pregnant and Lactating Women and Children
  
  
• NOT-HG-20-029: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Providing Research Experiences for Data Scientists
  
  
• NOT-OD-20-079: Notice of Special Interest (NOSI): Research to Improve the Interpretation of Patient-Reported Outcomes at the Individual Patient Level for Use in Clinical Practice
  
  
• NOT-OD-20-081: Notice of Special Interest: Research to Advance the Understanding of Tobacco Product Pharmacokinetic Research
  
  
• NOT-OD-20-084: Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)
  
  
• NOT-OD-20-085: Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)
  
  
• NOT-TR-20-011: Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
  
  

Other HHS Agencies and Offices

• ORI Guidance to Institutions Concerning Sequestration during Closure of Institutions Due to COVID-19
  
  
• ORI Operations Status during Public Health Emergency (COVID-19)
  
  

National Science Foundation

• NSF Innovation Corps (I-Corps)
  
  
• Dear Colleague Letter: Poorly Sampled and Unknown Taxa (PurSUiT)
  
  
• Important Notice No. 146: NSF Letter to Community Regarding COVID-19
  
  
• Dear Colleague Letter: Request for Information on Future Topics for the NSF Convergence Accelerator and Call for Future Topics Conference Proposals
  
  
• Dear Colleague Letter: International Collaboration Supplements in Quantum Information Science and Engineering Research
  
  
• Frequently Asked Questions (FAQs) for Signals in the Soil (SitS)
  
  
• Dear Colleague Letter: Mid-scale Research Infrastructure – Engineering Conferences
  
  
• Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
  
  
• Dear Colleague Letter: Developing Long-term Strategies to Transform Manufacturing
  
  
• Performance Audit of Incurred Costs – University of Connecticut (March 23, 2020)
  
  
• Audit of NSF’s Evaluation and Assessment Capability Section’s Use and Oversight of Contracts
  
  
• National Science Board April 1 Vision 2030 Task Force Teleconference
  
  
• 3/23/20 FR: Advisory Committee for Environmental Research and Education
  
  

NASA

• [none posted]
  
  

Department of Defense

• [none posted]
  
  

Office of Management and Budget

• [none posted]
  
  

Grants.gov

• [none posted]
  
  

Miscellaneous Agencies and Offices

• SAM.gov Scheduled Maintenance on Saturday, 03/28/2020 from 8:00 AM to 10:00 PM
  
  
• Funding Opportunity – Tribal Colleges Research Grants Program (NIFA)
  
  
• 3/25/20 FR: DOE/Biological and Environmental Research Advisory Committee; Meeting (DOE)
  
  

Federal Agency Weekly is an email transmitted on Friday afternoons to subscribers to MANAGING FEDERAL GRANTS for Colleges and Universities. It tracks federal grants policy issuances, rulemakings, guidance development and OIG reports and publications. The primary focus of Federal Agency Weekly is agency-wide grants management issues related to extramural research grants from NIH, NSF, NASA, and DOD, though broader coverage of NIH is provided with the inclusion of NIH program activities. In general, the specifics of individual funding opportunities are not covered.